OSELTAMIVIR POWDER FOR ORAL SUSPENSION POWDER FOR SUSPENSION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE)

থেকে পাওয়া:

STRIDES PHARMA CANADA INC

এটিসি কোড:

J05AH02

INN (আন্তর্জাতিক নাম):

OSELTAMIVIR

ডোজ:

6MG

ফার্মাসিউটিকাল ফর্ম:

POWDER FOR SUSPENSION

রচনা:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NEURAMINIDASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0139501005; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2020-12-30

পণ্য বৈশিষ্ট্য

_Pr_
_Oseltamivir Powder for Oral Suspension (oseltamivir phosphate) _
_Page 1 of 44 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
OSELTAMIVIR POWDER FOR ORAL SUSPENSION
oseltamivir powder for oral suspension
6 mg/mL oseltamivir (as oseltamivir phosphate) when reconstituted
House Standard
Antiviral Agent
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet,
Varennes, Quebec
Canada J3X 1P7
Date of Initial Authorization:
December 30, 2020
Date of Revision:
June 1, 2023
Submission Control Number: 270702
_Pr_
_Oseltamivir Powder for Oral Suspension (oseltamivir phosphate) _
_Page 2 of 44 _
RECENT MAJOR LABEL CHANGES
4 Dosage and Administration
06/2023
7 Warnings and Precautions, 7.1.1 Pregnant Women
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
5
1.2
Geriatrics
................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................................................